Abstract
A novel zoledronate derivative, 1-hydroxy-4-(2-butyl-1H-imidazol-1-yl)butane-1,1- diyldiphosphonic acid (BIBDP) was prepared and labeled with 99mTc successfully in a high radiochemical purity and good stability in vitro. The biodistribution in mice shows that 99mTc-BIBDP has high specificity and efficacy in bone uptake with a maximum of 12.14 ± 0.53 %ID/g at 120 min. Kinetics of blood clearance showed that distribution half life (T1/2α), elimination half life (T1/2β) and total clearance rate (CL) of 99mTc-BIBDP were 4.67 min, 91.9 min and 1.21 %ID/g·min-1, respectively. Moreover, 99mTc-BIBDP has higher uptake in the bone and faster clearance from soft tissues than 99mTc-MDP and 99mTc-ZL. A plain and clear bone image was obtained at 1 h with SPECT bone imaging. The present findings indicate that 99mTc- BIBDP holds great potential for bone imaging.
Keywords: Diphosphonic acid, 99mTc-labeled, Biodistribution, Pharmacokinetics, SPECT imaging
Current Radiopharmaceuticals
Title:A Novel 99mTc-labeled Diphosphonic Acid as Potential Bone Seeking Agent: Synthesis and Biological Evaluation
Volume: 6 Issue: 1
Author(s): Ling Qiu, Wen Cheng, Jianguo Lin, Shu Zhang and Shineng Luo
Affiliation:
Keywords: Diphosphonic acid, 99mTc-labeled, Biodistribution, Pharmacokinetics, SPECT imaging
Abstract: A novel zoledronate derivative, 1-hydroxy-4-(2-butyl-1H-imidazol-1-yl)butane-1,1- diyldiphosphonic acid (BIBDP) was prepared and labeled with 99mTc successfully in a high radiochemical purity and good stability in vitro. The biodistribution in mice shows that 99mTc-BIBDP has high specificity and efficacy in bone uptake with a maximum of 12.14 ± 0.53 %ID/g at 120 min. Kinetics of blood clearance showed that distribution half life (T1/2α), elimination half life (T1/2β) and total clearance rate (CL) of 99mTc-BIBDP were 4.67 min, 91.9 min and 1.21 %ID/g·min-1, respectively. Moreover, 99mTc-BIBDP has higher uptake in the bone and faster clearance from soft tissues than 99mTc-MDP and 99mTc-ZL. A plain and clear bone image was obtained at 1 h with SPECT bone imaging. The present findings indicate that 99mTc- BIBDP holds great potential for bone imaging.
Export Options
About this article
Cite this article as:
Qiu Ling, Cheng Wen, Lin Jianguo, Zhang Shu and Luo Shineng, A Novel 99mTc-labeled Diphosphonic Acid as Potential Bone Seeking Agent: Synthesis and Biological Evaluation, Current Radiopharmaceuticals 2013; 6 (1) . https://dx.doi.org/10.2174/1874471011306010005
DOI https://dx.doi.org/10.2174/1874471011306010005 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chemokines: Central Mediators of the Innate Response to Sepsis
Current Immunology Reviews (Discontinued) ABC Transporters: Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal Carcinoma
Current Medicinal Chemistry Amygdalin Decreases Adhesion and Migration of MDA-MB-231 and MCF-7 Breast Cancer Cell Lines
Current Molecular Pharmacology Therapeutic Applications of Capsaicin in Upper Airways
Current Drug Targets Translational Pharmacology in Aging Men with Benign Prostatic Hyperplasia: Molecular and Clinical Approaches to Alpha1-Adrenoceptors
Current Aging Science Pharmacological Activation of Protein Phosphatase 2 A (PP2A): A Novel Strategy to Fight Against Human Malignancies?
Current Medicinal Chemistry Radiolabelled Regulatory Peptides for Imaging and Therapy
Anti-Cancer Agents in Medicinal Chemistry Genetic and Molecular Approaches to the Immunopathogenesis of Multiple Sclerosis: An Update
Current Molecular Medicine Nitrogen-Containing Bisphosphonates and Cancer Immunotherapy
Current Pharmaceutical Design Identification of Drug Candidates for Breast Cancer Therapy Through Scaffold Repurposing: A Brief Review
Current Drug Research Reviews Angiotensin II Receptor Blocker: Possibility of Antitumor Agent for Prostate Cancer
Mini-Reviews in Medicinal Chemistry Clinical Management of Diabetes Mellitus in the Older Adult Patient
Current Diabetes Reviews Anticancer Effects of Cinnamaldehyde Through Inhibition of ErbB2/HSF1/LDHA Pathway in 5637 Cell Line of Bladder Cancer
Anti-Cancer Agents in Medicinal Chemistry Ferroptosis: A Trusted Ally in Combating Drug Resistance in Cancer
Current Medicinal Chemistry The Synergistic Effect of Humanized Monoclonal Antibodies Targeting Insulin-Like Growth Factor 1 Receptor (IGF-1R) and Chemotherapy
Current Drug Targets Current Status and Future Prospects of Small–molecule Protein–protein Interaction (PPI) Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL)
Current Topics in Medicinal Chemistry Modulation of k-Ras Signaling by Natural Products
Current Medicinal Chemistry Inorganic Nanoparticles for Enhanced Photodynamic Cancer Therapy
Current Drug Discovery Technologies TGR5 as a Therapeutic Target for Treating Obesity
Current Topics in Medicinal Chemistry Medicinal and Beneficial Health Applications of Tinospora cordifolia (Guduchi): A Miraculous Herb Countering Various Diseases/Disorders and its Immunomodulatory Effects
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)